Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2023-03-29 Earnings Release
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
Wybrane skonsolidowane dane finansowe za 2022
Earnings Release Classification · 99% confidence The document text consists primarily of consolidated financial data presented in tables, showing key metrics like revenue, profit/loss, cash flows, and balance sheet items for the years 2022 and 2021, denominated in Polish Złoty (zł) and Euros (EUR). The title mentions 'Raport WYBRANE SKONSOLIDOWANE DANE FINANSOWE' (Report SELECTED CONSOLIDATED FINANCIAL DATA). This structure strongly indicates a presentation of periodic financial results. Since the data covers a full year (ending 31.12.2022 and 31.12.2021) and contains comprehensive financial statements elements, it aligns best with an Annual Report (10-K) or an Interim/Quarterly Report (IR). Given the year-end dates and the depth of data, it is most likely part of the annual reporting cycle, although it might be an excerpt or supplement. However, the presence of detailed comparative annual figures suggests it is either the 10-K or a detailed component thereof. If it were a short announcement, it would be RPA/ER. Since it contains the actual detailed figures, it is classified as a comprehensive report. Given the context of global filings, if this were a US filer, it would be a 10-K. For non-US filers presenting full annual data, 'AR' (Audit Report/Information) is sometimes used for comprehensive reports that aren't the primary 10-K filing, but '10-K' is the standard for full annual performance review. Since the data is comprehensive and covers a full fiscal year comparison, 10-K is the most appropriate fit among the options for a full annual financial disclosure, even if the source language is Polish. If it were only quarterly data, IR would be better. Since it is year-end data, 10-K is selected. FY 2022
2023-03-29 Polish
List Prezesa Zarządu - Grupa Kapitałowa - podpis
Regulatory Filings Classification · 95% confidence The provided document text consists entirely of XML structures related to digital signatures (specifically XAdES/XML-DSig), containing elements like <Signatures>, <SignedInfo>, <SignatureValue>, and <KeyInfo> with X.509 certificates. The file name referenced within the signature block is "Pharmena_pismo_GK_2022.xhtml". This structure strongly suggests the document is a digitally signed file, likely a regulatory submission or official communication that has been signed for authenticity and integrity. Since the content is purely metadata about the signature and not the actual financial report content (like an ER, 10-K, or IR), it does not fit any of the specific financial report categories (10-K, ER, IR, etc.). Therefore, the most appropriate classification is the general fallback category for miscellaneous regulatory filings or attachments that don't fit elsewhere, which is Regulatory Filings (RNS). The document length is 9935 characters, which is substantial, but the content is entirely signature metadata, not the report itself, thus avoiding the RPA classification.
2023-03-29 Polish
List Prezesa Zarządu - Grupa Kapitałowa
Audit Report / Information Classification · 95% confidence The document is a letter from the CEO (Prezes Zarządu) presenting the 'raport za 2022 rok' (report for 2022). It summarizes key financial figures (revenues, profit/loss) for the year 2022, discusses business activities (product portfolio expansion, R&D on 1-MNA), and outlines future plans. This content structure—a high-level summary of the past year's performance and outlook, often signed by management—is characteristic of an Annual Report (10-K) or a Management Discussion & Analysis (MDA) section thereof. Since the text provides a comprehensive summary of the full year's performance and outlook, it strongly aligns with the content expected in an Annual Report (10-K) or a detailed Management Report (MDA). Given the context of a full-year review, 10-K is the most appropriate primary classification for the underlying report being summarized, but the text itself reads like a management commentary/MD&A. However, since the text is a summary of the *full year* performance and outlook, and not just a short announcement of a report's release, it fits the content of a comprehensive annual filing. If this were a standalone document, it would be MDA. If it is the narrative part of the official annual filing, it is 10-K. Given the comprehensive nature covering the entire year and future outlook, I will classify it as 10-K, as it represents the core narrative of the annual filing. FY 2022
2023-03-29 Polish
Oświadczenie Rady Nadzorczej ws. audytora i komitetu audytu
Audit Report / Information Classification · 99% confidence The document is titled 'Raport 1 OŚWIADCZENIE RADY NADZORCZEJ PHARMENA S.A.' (Report 1 STATEMENT OF THE SUPERVISORY BOARD OF PHARMENA S.A.) and specifically addresses the selection of the auditing firm ('OŚWIADCZENIE DOTYCZĄCE POLITYKI WYBORU FIRMY AUDYTORSKIEJ'). It details compliance with regulations regarding the audit of annual financial statements and the functioning of the Audit Committee. This content directly relates to the formal audit process, accounting principles, and internal oversight structure, but it is a specific statement/report about the audit process rather than the full annual report (10-K) or a general audit opinion. Given the options, 'Audit Report / Information' (AR) is the most appropriate fit as it covers standalone audit reports and applied accounting principles/internal stress tests, which aligns with the supervisory board's statement regarding the auditor selection and compliance. FY 2022
2023-03-29 Polish
Oświadczenie Ocena Rady Nadzorczej za badania SF za 2022
Audit Report / Information Classification · 98% confidence The document is titled "Raport 1 OCENA RADY NADZORCZEJ PHARMENA S.A. DOTYCZĄCA SPRAWOZDANIA ZARZĄDU Z DZIAŁALNOŚCI GRUPY KAPITAŁOWEJ PHARMENA S.A. I PHARMENA S.A. ZA 2022 ROK, JEDNOSTKOWEGO SPRAWOZDANIA FINANSOWEGO..." (Report 1 ASSESSMENT BY THE SUPERVISORY BOARD OF PHARMENA S.A. CONCERNING THE MANAGEMENT BOARD'S REPORT ON THE ACTIVITIES OF THE PHARMENA S.A. CAPITAL GROUP AND PHARMENA S.A. FOR 2022, THE INDIVIDUAL FINANCIAL STATEMENT...). It details the Supervisory Board's assessment of the Management Board's activity report and the individual and consolidated financial statements for the year ended December 31, 2022. This document is an assessment/opinion provided by the Supervisory Board regarding the annual financial reports and management report, which is a key component of corporate governance and audit oversight, but it is not the full Annual Report (10-K) itself, nor is it a standalone Audit Report (AR) which typically contains the auditor's opinion. It is a formal review/assessment document. Given the options, it most closely relates to Governance Information (CGR) as it details the board's review process and findings on statutory reports, or potentially an Audit Report/Information (AR) if interpreted broadly as related to the audit results review. However, since it is explicitly the Supervisory Board's assessment of the financial statements and management report, CGR (Governance Information) is the most appropriate fit, as it concerns internal oversight and governance practices related to reporting. FY 2022
2023-03-29 Polish
Informacja zarządu ws wyboru audytora za 2022 - podpis
Regulatory Filings Classification · 95% confidence The provided document text consists entirely of XML Digital Signature blocks (specifically XAdES signatures) used for verifying the authenticity and integrity of another document. The content references a file named "Pharmena_inform_zarzadu_ws_wyboru_audytora_2022.xhtml". The presence of signatures and the reference to an external document strongly suggest this is not the primary report itself, but rather metadata or a wrapper file. Since the content is purely technical validation data and does not contain financial narratives, results, or standard regulatory disclosures (like 10-K, ER, or IR), it falls best into the general regulatory/miscellaneous category, which is 'Regulatory Filings' (RNS), as it is a technical filing component rather than a specific financial report type. The document length is also relatively short for a full report.
2023-03-29 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.